Frank Fan, Legend founder and former CSO

Af­ter steer­ing made-in-Chi­na CAR-T all the way from ob­scu­ri­ty to ap­proval, Frank Fan re­signs from Leg­end

Now that Leg­end Biotech has se­cured its first ap­proval for the J&J-part­nered BC­MA CAR-T, it’s say­ing good­bye to its founder and CSO.

Frank Fan — who be­gan work­ing on the cell ther­a­py in 2014 when it was still housed in the Chi­nese CRO Gen­Script, took it to the in­ter­na­tion­al spot­light at 2017’s AS­CO con­fer­ence with stun­ning da­ta, ne­go­ti­at­ed a deal with J&J’s Janssen for it with $350 mil­lion up­front and steered it to an FDA OK days ago — re­signed from the com­pa­ny ef­fec­tive March 30, the com­pa­ny re­vealed Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.